A citation-based method for searching scientific literature

Boudewijn Dullens, Robin de Putter, Matteo Lambertini, Angela Toss, Sileny Han, Els Van Nieuwenhuysen, Toon Van Gorp, Adriaan Vanderstichele, Chantal Van Ongeval, Machteld Keupers, Renate Prevos, Valerie Celis, Jeroen Dekervel, Wouter Everaerts, Hans Wildiers, Ines Nevelsteen, Patrick Neven, Dirk Timmerman, Ann Smeets, Ellen Denayer, Griet Van Buggenhout, Eric Legius, Kevin Punie. J Oncol 2020
Times Cited: 10







List of co-cited articles
53 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Cancer Incidence in BRCA1 mutation carriers.
Deborah Thompson, Douglas F Easton. J Natl Cancer Inst 2002
756
30

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
Kara N Maxwell, Bradley Wubbenhorst, Brandon M Wenz, Daniel De Sloover, John Pluta, Lyndsey Emery, Amanda Barrett, Adam A Kraya, Ioannis N Anastopoulos, Shun Yu,[...]. Nat Commun 2017
134
30

Biallelic inactivation of BRCA2 in Fanconi anemia.
Niall G Howlett, Toshiyasu Taniguchi, Susan Olson, Barbara Cox, Quinten Waisfisz, Christine De Die-Smulders, Nicole Persky, Markus Grompe, Hans Joenje, Gerard Pals,[...]. Science 2002
868
30

Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.
Alexandra J van den Broek, Laura J van 't Veer, Maartje J Hooning, Sten Cornelissen, Annegien Broeks, Emiel J Rutgers, Vincent T H B M Smit, Cees J Cornelisse, Mike van Beek, Maryska L Janssen-Heijnen,[...]. J Clin Oncol 2016
57
20

Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
Nasim Mavaddat, Susan Peock, Debra Frost, Steve Ellis, Radka Platte, Elena Fineberg, D Gareth Evans, Louise Izatt, Rosalind A Eeles, Julian Adlard,[...]. J Natl Cancer Inst 2013
532
20

Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.
Karoline B Kuchenbaecker, John L Hopper, Daniel R Barnes, Kelly-Anne Phillips, Thea M Mooij, Marie-José Roos-Blom, Sarah Jervis, Flora E van Leeuwen, Roger L Milne, Nadine Andrieu,[...]. JAMA 2017
20

Oestrogen receptor status, treatment and breast cancer prognosis in Icelandic BRCA2 mutation carriers.
Jon G Jonasson, Olafur A Stefansson, Oskar T Johannsson, Helgi Sigurdsson, Bjarni A Agnarsson, Gudridur H Olafsdottir, Kristin K Alexiusdottir, Hrefna Stefansdottir, Rodrigo Munoz Mitev, Katrin Olafsdottir,[...]. Br J Cancer 2016
27
20

The Icelandic founder mutation BRCA2 999del5: analysis of expression.
Evgenia K Mikaelsdottir, Sigridur Valgeirsdottir, Jorunn E Eyfjord, Thorunn Rafnar. Breast Cancer Res 2004
37
20


The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial.
Shahneen K Sandhu, William R Schelman, George Wilding, Victor Moreno, Richard D Baird, Susana Miranda, Lucy Hylands, Ruth Riisnaes, Martin Forster, Aurelius Omlin,[...]. Lancet Oncol 2013
375
20

Dissociation of p53-mediated suppression of homologous recombination from G1/S cell cycle checkpoint control.
H Willers, E E McCarthy, B Wu, H Wunsch, W Tang, D G Taghian, F Xia, S N Powell. Oncogene 2000
87
20

Chromosomes, sex chromatin, and cancer.
M L BARR, K L MOORE. Proc Can Cancer Conf 1957
24
20

Allele-specific copy number analysis of tumors.
Peter Van Loo, Silje H Nordgard, Ole Christian Lingjærde, Hege G Russnes, Inga H Rye, Wei Sun, Victor J Weigman, Peter Marynen, Anders Zetterberg, Bjørn Naume,[...]. Proc Natl Acad Sci U S A 2010
640
20

DNA damage response protein TOPBP1 regulates X chromosome silencing in the mammalian germ line.
Elias ElInati, Helen R Russell, Obah A Ojarikre, Mahesh Sangrithi, Takayuki Hirota, Dirk G de Rooij, Peter J McKinnon, James M A Turner. Proc Natl Acad Sci U S A 2017
22
20

Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.
Johann de Bono, Ramesh K Ramanathan, Lida Mina, Rashmi Chugh, John Glaspy, Saeed Rafii, Stan Kaye, Jasgit Sachdev, John Heymach, David C Smith,[...]. Cancer Discov 2017
240
20

Pan-cancer landscape of homologous recombination deficiency.
Luan Nguyen, John W M Martens, Arne Van Hoeck, Edwin Cuppen. Nat Commun 2020
94
20


Tumour lineage shapes BRCA-mediated phenotypes.
Philip Jonsson, Chaitanya Bandlamudi, Michael L Cheng, Preethi Srinivasan, Shweta S Chavan, Noah D Friedman, Ezra Y Rosen, Allison L Richards, Nancy Bouvier, S Duygu Selcuklu,[...]. Nature 2019
174
20

The Cancer Genome Atlas: Creating Lasting Value beyond Its Data.
Carolyn Hutter, Jean Claude Zenklusen. Cell 2018
253
20

DNA repair pathway gene expression score correlates with repair proficiency and tumor sensitivity to chemotherapy.
Sean P Pitroda, Itai M Pashtan, Hillary L Logan, Brian Budke, Thomas E Darga, Ralph R Weichselbaum, Philip P Connell. Sci Transl Med 2014
63
20

SMCHD1 promotes ATM-dependent DNA damage signaling and repair of uncapped telomeres.
Aleksandra Vančevska, Wareed Ahmed, Verena Pfeiffer, Marianna Feretzaki, Simon J Boulton, Joachim Lingner. EMBO J 2020
9
22

Signatures of mutational processes in human cancer.
Ludmil B Alexandrov, Serena Nik-Zainal, David C Wedge, Samuel A J R Aparicio, Sam Behjati, Andrew V Biankin, Graham R Bignell, Niccolò Bolli, Ake Borg, Anne-Lise Børresen-Dale,[...]. Nature 2013
20


Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
V Abkevich, K M Timms, B T Hennessy, J Potter, M S Carey, L A Meyer, K Smith-McCune, R Broaddus, K H Lu, J Chen,[...]. Br J Cancer 2012
380
20

Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review.
B Pellegrino, A Musolino, A Llop-Guevara, V Serra, P De Silva, Z Hlavata, D Sangiolo, K Willard-Gallo, C Solinas. Transl Oncol 2020
28
20

A role for the p53 tumour suppressor in regulating the balance between homologous recombination and non-homologous end joining.
Sylvie Moureau, Janna Luessing, Emma Christina Harte, Muriel Voisin, Noel Francis Lowndes. Open Biol 2016
21
20

A mutational signature reveals alterations underlying deficient homologous recombination repair in breast cancer.
Paz Polak, Jaegil Kim, Lior Z Braunstein, Rosa Karlic, Nicholas J Haradhavala, Grace Tiao, Daniel Rosebrock, Dimitri Livitz, Kirsten Kübler, Kent W Mouw,[...]. Nat Genet 2017
267
20



Absolute quantification of somatic DNA alterations in human cancer.
Scott L Carter, Kristian Cibulskis, Elena Helman, Aaron McKenna, Hui Shen, Travis Zack, Peter W Laird, Robert C Onofrio, Wendy Winckler, Barbara A Weir,[...]. Nat Biotechnol 2012
20

Inhibition of Atm and/or Atr disrupts gene silencing on the inactive X chromosome.
Yan Ouyang, Jennifer Salstrom, Silvia Diaz-Perez, Shareef Nahas, Youko Matsuno, David Dawson, Michael A Teitell, Steve Horvath, Arthur D Riggs, Richard A Gatti,[...]. Biochem Biophys Res Commun 2005
11
20

Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer.
Tamara L Lotan, Harsimar B Kaur, Daniela C Salles, Sanjana Murali, Edward M Schaeffer, Jerry S Lanchbury, William B Isaacs, Robert Brown, Andrea L Richardson, Olivier Cussenot,[...]. Mod Pathol 2021
21
20

Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.
Tatiana Popova, Elodie Manié, Guillaume Rieunier, Virginie Caux-Moncoutier, Carole Tirapo, Thierry Dubois, Olivier Delattre, Brigitte Sigal-Zafrani, Marc Bollet, Michel Longy,[...]. Cancer Res 2012
342
20


Correlation of homologous recombination deficiency induced mutational signatures with sensitivity to PARP inhibitors and cytotoxic agents.
Ádám Póti, Hella Gyergyák, Eszter Németh, Orsolya Rusz, Szilárd Tóth, Csenger Kovácsházi, Dan Chen, Bernadett Szikriszt, Sándor Spisák, Shunichi Takeda,[...]. Genome Biol 2019
48
20

Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Melinda L Telli, Kirsten M Timms, Julia Reid, Bryan Hennessy, Gordon B Mills, Kristin C Jensen, Zoltan Szallasi, William T Barry, Eric P Winer, Nadine M Tung,[...]. Clin Cancer Res 2016
438
20

HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures.
Helen Davies, Dominik Glodzik, Sandro Morganella, Lucy R Yates, Johan Staaf, Xueqing Zou, Manasa Ramakrishna, Sancha Martin, Sandrine Boyault, Anieta M Sieuwerts,[...]. Nat Med 2017
436
20

Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.
Helen E Bryant, Niklas Schultz, Huw D Thomas, Kayan M Parker, Dan Flower, Elena Lopez, Suzanne Kyle, Mark Meuth, Nicola J Curtin, Thomas Helleday. Nature 2005
20

Tumor mutation burden forecasts outcome in ovarian cancer with BRCA1 or BRCA2 mutations.
Nicolai Juul Birkbak, Bose Kochupurakkal, Jose M G Izarzugaza, Aron C Eklund, Yang Li, Joyce Liu, Zoltan Szallasi, Ursula A Matulonis, Andrea L Richardson, J Dirk Iglehart,[...]. PLoS One 2013
103
20

Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity.
Ethan S Sokol, Dean Pavlick, Hossein Khiabanian, Garrett M Frampton, Jeffrey S Ross, Jeffrey P Gregg, Primo N Lara, Steffi Oesterreich, Neeraj Agarwal, Andrea Necchi,[...]. JCO Precis Oncol 2020
51
20

Regulation and pharmacological targeting of RAD51 in cancer.
McKenzie K Grundy, Ronald J Buckanovich, Kara A Bernstein. NAR Cancer 2020
21
20

BRCAness revisited.
Christopher J Lord, Alan Ashworth. Nat Rev Cancer 2016
676
20

International network of cancer genome projects.
Thomas J Hudson, Warwick Anderson, Axel Artez, Anna D Barker, Cindy Bell, Rosa R Bernabé, M K Bhan, Fabien Calvo, Iiro Eerola, Daniela S Gerhard,[...]. Nature 2010
20

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.
Nicolai J Birkbak, Zhigang C Wang, Ji-Young Kim, Aron C Eklund, Qiyuan Li, Ruiyang Tian, Christian Bowman-Colin, Yang Li, April Greene-Colozzi, J Dirk Iglehart,[...]. Cancer Discov 2012
293
20

Human genes escaping X-inactivation revealed by single cell expression data.
Kerem Wainer Katsir, Michal Linial. BMC Genomics 2019
34
20

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1.
David A Barbie, Pablo Tamayo, Jesse S Boehm, So Young Kim, Susan E Moody, Ian F Dunn, Anna C Schinzel, Peter Sandy, Etienne Meylan, Claudia Scholl,[...]. Nature 2009
20

Two genetic hits (more or less) to cancer.
A G Knudson. Nat Rev Cancer 2001
640
20

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
20

Clinical assays for assessment of homologous recombination DNA repair deficiency.
Elizabeth H Stover, Katherine Fuh, Panagiotis A Konstantinopoulos, Ursula A Matulonis, Joyce F Liu. Gynecol Oncol 2020
25
20

PARP Inhibitors in Metastatic Prostate Cancer: Evidence to Date.
Emily Nizialek, Emmanuel S Antonarakis. Cancer Manag Res 2020
29
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.